Abstract
The established biomarkers of Alzheimer’s disease (AD) require invasive endeavours or presuppose sophisticated technical equipment. Consequently, new biomarkers are needed. Here, we report that plasma levels of soluble amyloid precursor protein β (sAPPβ), a protein of the initial phase of the amyloid cascade, were significantly lower in patients with symptomatic AD (21 with mild cognitive impairment due to AD and 44 with AD dementia) with AD-typical cerebral hypometabolic pattern compared with 27 cognitively healthy elderly individuals without preclinical AD. These findings yield further evidence for the potential of sAPPβ in plasma as an AD biomarker candidate.
References
Dubois B, Feldman HH, Jacova C et al (2014) Advancing research diagnostic criteria for Alzheimer’s disease: the IWG-2 criteria. Lancet Neurol 13(6):614–629. doi:10.1016/S1474-4422(14)70090-0
McKhann GM (2011) Changing concepts of Alzheimer disease. JAMA 305(23):2458–2459. doi:10.1001/jama.2011.810
Alexopoulos P, Kurz A (2015) The new conceptualization of Alzheimer’s disease under the microscope of influential definitions of disease. Psychopathology 48(6):359–367. doi:10.1159/000441327
Martins-de-Souza D (2010) Is the word ‘biomarker’ being properly used by proteomics research in neuroscience? Eur Arch Psychiatry Clin Neurosci 260(7):561–562. doi:10.1007/s00406-010-0105-2
Herukka S-K, Simonsen AH, Andreasen N et al (2017) Recommendations for cerebrospinal fluid Alzheimer’s disease biomarkers in the diagnostic evaluation of mild cognitive impairment. Alzheimer’s Dement 13(3):285–295. doi:10.1016/j.jalz.2016.09.009
Simonsen AH, Herukka S-K, Andreasen N et al (2017) Recommendations for CSF AD biomarkers in the diagnostic evaluation of dementia. Alzheimer’s Dement 13(3):274–284. doi:10.1016/j.jalz.2016.09.008
Plassman BL, Khachaturian AS, Townsend JJ et al (2006) Comparison of clinical and neuropathologic diagnoses of Alzheimer’s disease in 3 epidemiologic samples. Alzheimer’s Dement 2(1):2–11. doi:10.1016/j.jalz.2005.11.001
Weiner MW, Veitch DP, Aisen PS et al (2017) Recent publications from the Alzheimer’s disease neuroimaging initiative: reviewing progress toward improved AD clinical trials. Alzheimer’s Dement. doi:10.1016/j.jalz.2016.11.007
Skillbäck T, Farahmand BY, Rosén C et al (2015) Cerebrospinal fluid tau and amyloid-β1-42 in patients with dementia. Brain 138(9):2716–2731. doi:10.1093/brain/awv181
Alexopoulos P, Kriett L, Haller B et al (2014) Limited agreement between biomarkers of neuronal injury at different stages of Alzheimer’s disease. Alzheimer’s Dement 10(6):684–689. doi:10.1016/j.jalz.2014.03.006
Alexopoulos P, Roesler J, Thierjung N et al (2015) Mapping CSF biomarker profiles onto NIA-AA guidelines for Alzheimer’s disease. Eur Arch Psychiatry Clin Neurosci. doi:10.1007/s00406-015-0628-7
McKhann GM, Knopman DS, Chertkow H et al (2011) The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimer’s Dement 7(3):263–269. doi:10.1016/j.jalz.2011.03.005
Albert MS, DeKosky ST, Dickson D et al (2011) The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimer’s Dement 7(3):270–279. doi:10.1016/j.jalz.2011.03.008
Petersen RC, Aisen P, Boeve BF et al (2013) Mild cognitive impairment due to Alzheimer disease in the community. Ann Neurol 74(2):199–208. doi:10.1002/ana.23931
Perneczky R, Alexopoulos P, Kurz A (2014) Soluble amyloid precursor proteins and secretases as Alzheimer’s disease biomarkers. Trends Mol Med 20(1):8–15
Smailagic N, Vacante M, Hyde C (2015) 18F-FDG PET for the early diagnosis of Alzheimer’s disease dementia and other dementias in people with mild cognitive impairment (MCI). Cochrane Database Syst Rev 1:CD010632. doi:10.1002/14651858.CD010632.pub2
Perneczky R, Guo LH, Kagerbauer SM et al (2013) Soluble amyloid precursor protein beta as blood-based biomarker of Alzheimer’s disease. Transl Psychiatry 3:e227. doi:10.1038/tp.2013.11
Wu G, Sankaranarayanan S, Hsieh SH-K et al (2011) Decrease in brain soluble amyloid precursor protein beta (sAPPbeta) in Alzheimer’s disease cortex. J Neurosci Res 89(6):822–832. doi:10.1002/jnr.22618
Alexopoulos P, Grimmer T, Perneczky R et al (2006) Progression to dementia in clinical subtypes of mild cognitive impairment. Dement Geriatr Cogn Disord 22(1):27–34. doi:10.1159/000093101
Perneczky R, Drzezga A, Boecker H et al (2010) Metabolic alterations associated with impaired clock drawing in Lewy body dementia. Psychiatry Res 181(2):85–89. doi:10.1016/j.pscychresns.2009.08.001
Alexopoulos P, Guo L-H, Jiang M et al (2013) Amyloid cascade and tau pathology cerebrospinal fluid markers in mild cognitive impairment with regards to Alzheimer’s disease cerebral metabolic signature. J Alzheimers Dis 36(2):401–408. doi:10.3233/JAD-122329
Jagust WJ, Landau SM, Shaw LM et al (2009) Relationships between biomarkers in aging and dementia. Neurology 73(15):1193–1199. doi:10.1212/WNL.0b013e3181bc010c
Hulstaert F, Blennow K, Ivanoiu A et al (1999) Improved discrimination of AD patients using beta-amyloid (1–42) and tau levels in CSF. Neurology 52(8):1555–1562
Wenham PR, Price WH, Blandell G (1991) Apolipoprotein E genotyping by one-stage PCR. Lancet (London, England) 337(8750):1158–1159
Olsson B, Lautner R, Andreasson U et al (2016) CSF and blood biomarkers for the diagnosis of Alzheimer’s disease. A systematic review and meta-analysis. Lancet Neurol 15(7):673–684. doi:10.1016/S1474-4422(16)00070-3
Zhang S, Smailagic N, Hyde C et al. (2014) 11C-PIB-PET for the early diagnosis of Alzheimer’s disease dementia and other dementias in people with mild cognitive impairment (MCI). Cochrane Database Syst Rev (7):CD010386. doi:10.1002/14651858.CD010386.pub2
Wu G, Sankaranarayanan S, Tugusheva K et al (2008) Decrease in age-adjusted cerebrospinal fluid beta-secretase activity in Alzheimer’s subjects. Clin Biochem 41(12):986–996. doi:10.1016/j.clinbiochem.2008.04.022
Kitazume S, Yoshihisa A, Yamaki T et al (2012) Soluble amyloid precursor protein 770 is released from inflamed endothelial cells and activated platelets: a novel biomarker for acute coronary syndrome. J Biol Chem 287(48):40817–40825. doi:10.1074/jbc.M112.398578
Marksteiner J, Humpel C (2013) Platelet-derived secreted amyloid-precursor protein-beta as a marker for diagnosing Alzheimer’s disease. Curr Neurovasc Res 10(4):297–303
Delvaux E, Bentley K, Stubbs V et al (2013) Differential processing of amyloid precursor protein in brain and in peripheral blood leukocytes. Neurobiol Aging 34(6):1680–1686. doi:10.1016/j.neurobiolaging.2012.12.004
Xiang Y, Bu X-L, Liu Y-H et al (2015) Physiological amyloid-beta clearance in the periphery and its therapeutic potential for Alzheimer’s disease. Acta Neuropathol 130(4):487–499. doi:10.1007/s00401-015-1477-1
Roher AE, Esh CL, Kokjohn TA et al (2009) Amyloid beta peptides in human plasma and tissues and their significance for Alzheimer’s disease. Alzheimer’s Dement 5(1):18–29. doi:10.1016/j.jalz.2008.10.004
Vignini A, Sartini D, Morganti S et al (2011) Platelet amyloid precursor protein isoform expression in Alzheimer’s disease: evidence for peripheral marker. Int J Immunopathol Pharmacol 24(2):529–534
Jiang S, Zhang M, Ren D et al (2003) Enhanced production of amyloid precursor protein mRNA by peripheral mononuclear blood cell in Alzheimer’s disease. American journal of medical genetics. Part B Psychiatr Genet 118B(1):99–102. doi:10.1002/ajmg.b.10067
Chasseigneaux S, Allinquant B (2012) Functions of Abeta, sAPPalpha and sAPPbeta. Similarities and differences. J Neurochem 120(1):99–108. doi:10.1111/j.1471-4159.2011.07584.x
Kitazume S, Yoshihisa A, Yamaki T et al (2012) Soluble amyloid precursor protein 770 is released from inflamed endothelial cells and activated platelets: a novel biomarker for acute coronary syndrome. J Bio Chem 287(48):40817–40825. doi:10.1074/jbc.M112.398578
Alexopoulos P, Roesler J, Thierjung N et al (2015) Mapping CSF biomarker profiles onto NIA-AA guidelines for Alzheimer’s disease. Eur Arch Psychiatry Clin Neurosci. doi:10.1007/s00406-015-0628-7
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
All authors declare that they have no conflict of interest.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Alexopoulos, P., Gleixner, LS., Werle, L. et al. Plasma levels of soluble amyloid precursor protein β in symptomatic Alzheimer’s disease. Eur Arch Psychiatry Clin Neurosci 268, 519–524 (2018). https://doi.org/10.1007/s00406-017-0815-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00406-017-0815-9